505584396 07/23/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5631195

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JEAN MAZELLA	07/10/2019
MARC BORSOTTO	07/10/2019
CATHERINE HEURTEAUX	07/10/2019
ALAEDDINE DJILLANI	07/02/2019
SÉBASTIEN MORENO	07/08/2019
MARIEL PIETRI	07/10/2019

RECEIVING PARTY DATA

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
3, RUE MICHEL ANGE
PARIS
FRANCE
75016
UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS
GRAND CHÂTEAU 28 AVENUE DE VALROSE
NICE
FRANCE
110000

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16340832

CORRESPONDENCE DATA

Fax Number: (703)685-0573

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7035212297

Email: NLeta@young-thompson.com

Correspondent Name: YOUNG & THOMPSON

Address Line 1: 209 MADISON STREET, SUITE 500 Address Line 4: ALEXANDRIA, VIRGINIA 223141764

PATENT REEL: 049830 FRAME: 0584

505584396

ATTORNEY DOCKET NUMBER:	0512-2012
NAME OF SUBMITTER:	ERIC JENSEN
SIGNATURE:	/Eric Jensen/
DATE SIGNED:	07/23/2019
Total Attachments: 2 source=ASSMT#page1.tif source=ASSMT#page2.tif	

PATENT REEL: 049830 FRAME: 0585

US - BET 19P0929 - APE

Peptides derived from the propeptide NTSR3 and their use in the treatment of depression

ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63 (For Use with Signed Application Data Sheet)

	eptides derived from the prope epression	ptide NTSR3 and their use in the treatment of
Attorney Docket No.:		
the attached applicat		e): given above and claiming priority of the patent
Country	Date	Application No.
France France France	11/10/2016 16/03/2017 11/05/2017	1659781 1752162 17 54127

United States Application or PCT International Application No.PCT/FR2017/052788, filed 11 October 2017.

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as a below-named inventor I have sold and assigned, and hereby sell and assign, to:

Name of Assignee: Centre national de la recherche scientifique Address of Assignee: 3, rue Michel Ange 75016 PARIS FRANCE Name of Assignee: UNIVERSITE DE NICE SOPHIA ANTIPOLIS

Address of Assignee: Grand Château 28 avenue de Valrose 06000 NICE FRANCE

(hereinafter ASSIGNEE) all right, title, and interest in and to the above-identified invention and United States patent application, including: (i) any and all divisions or continuations thereof, and in and to any and all Letters Patent of the United States that may issue on any such application or for said invention, including any and all reissues or extensions thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such Letters Patent may be granted; (ii) all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted; and (iii) all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted.

I hereby authorize and request the Director of the U.S. Patent and Trademark Office to issue any and all such Letters Patent to said ASSIGNEE, its successors, or assigns in accordance herewith.

I warrant and covenant that I have the right to sell and assign the interests herein sold and assigned and that I have not executed and will not execute any document or instrument in conflict herewith.

I further covenant and agree that I will communicate to said ASSIGNEE, its successors, legal representatives, or assigns all information known to me relating to said invention or patent application and that I will execute and deliver any papers, make all rightful oaths, testify in any legal proceedings, and perform all other lawful acts necessary or desirable by said ASSIGNEE, its successors, legal representatives, or assigns to perfect title to said invention, to said application including divisions and

Page 1 of 2

Peptides derived from the propeptide NTSR3 and their use in the treatment of depression

ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63 (For Use with Signed Application Data Sheet)

continuations thereof and to any and all Letters Patent that may be granted therefor or thereon, including reissues or extensions, in said ASSIGNEE, its successors, or assigns, or to assist said ASSIGNEE, its successors, legal representatives, or assigns in obtaining, reissuing, or enforcing Letters Patent of the United States and any and all patents, utility models, designs or other rights that may be granted in the United States or of any country or countries foreign to the United States, for said invention.

DECLARATION

As a below-named inventor, I hereby declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature:	Date:july 10th 2019
Inventor: MAZELLA Jean	
Signature:	
Inventor: BORSOTTO Marc	Date :july 10th 2019
Signature:	
Inventor: HEURTEAUX Catherine	Date:july 10th 2019
Signature:	
Inventor: DJILLANI Alaeddine	Date:july 2nd 2019
Signature:	
Inventor: MORENO Sébastien	Date:july 8 th 2019
Signature:	
Inventor: PIETRI Mariel	Date:july 10th 2019